Loading…
New Product Planning Summit has ended
Back To Schedule
Wednesday, February 3 • 11:35am - 12:20pm
Panel: Navigating the Early Commercial Strategy Waters: Cell Therapy vs. Non-Cell Therapy

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Feedback form is now closed.
  • Assess key stakeholders in a medication’s lifecycle and how they should impact NPP
  • Discuss critical elements to NPP within the context of cell therapy and non-cell therapy
  • Determine key challenges for various product categories and how to mitigate them
Moderators
avatar for Tony Russell, Ph.D., M.B.A.

Tony Russell, Ph.D., M.B.A.

Executive Director, New Product Planning, Chinook Therapeutics, Inc.
Tony Russell is currently the Head and Executive Director of New Product Planning at Chinook Therapeutics with a focus on developing precision medicines for kidney diseases. With over 20 years of industry experience, Tony has worked across multiple facets in the biopharmaceutical... Read More →

Speakers
avatar for Lung-I Cheng, Ph.D.

Lung-I Cheng, Ph.D.

Global Value & Access Lead, Cell Therapies, Takeda
Lung-I Cheng, PhD, is Global Value & Access Lead, Cell Therapies at Takeda Pharmaceuticals. In this role, he leads the access strategy for Takeda's portfolio of cell therapy assets in oncology. Prior to this, he oversaw the market access efforts for the company's lymphoma franchise... Read More →
avatar for Kelly Page

Kelly Page

Head of Global Cell Therapy Commercialization, Takeda
Kelly Page is Head of Global Cell Therapy Commercialization, Global Oncology Business Unit at Takeda Pharmaceuticals. Previous roles within Takeda’s Oncology Business Unit have included Country Head for Germany and Global Development Lead for ADCETRIS, where she oversaw the first... Read More →
avatar for Jennifer Sherak

Jennifer Sherak

Global Head, Oncology New Products, Takeda
Jennifer is currently the Global Head of Oncology New Product Planning Business Development at Takeda Pharmaceuticals. In her current role, she is responsible for ensuring that the value of the oncology pipeline is maximized globally by integrating commercial insights early in development... Read More →

Wednesday February 3, 2021 11:35am - 12:20pm EST
  General Session

Attendees (17)